Brief: Tetra Bio Pharma- FDA says Co's Caumz Kit Can Be Evaluated As Combination Drug/Device Product
Oct 3 (Reuters) - Tetra Bio Pharma Inc TBP.V :
* TETRA BIO-PHARMA PROVIDES REGULATORY UPDATE FOR ITS
CAUMZ(TM)
KIT
* TETRA BIO PHARMA INC - FDA HAS DETERMINED THAT COMPANY'S
CAUMZ
KIT CAN BE EVALUATED AS A COMBINATION DRUG/DEVICE PRODUCT
* TETRA BIO PHARMA INC - CAUMZ KIT HAS BEEN ASSIGNED TO
CENTER FOR
DRUG EVALUATION AND RESEARCH FOR PREMARKET REVIEW
Source text for Eikon: ID:nGNX8G8CgW
Further company coverage: TBP.V
(Reporting by Trisha Roy)
((Trisha.Roy@thomsonreuters.com;))
Recent news on Tetra Bio Pharma
See all newsBrief: Tetra Bio Receives A Second Clarifax From Health Canada Regarding Reduvo Risk Management Plan
Brief: Tetra Bio-Pharma Announces Results Of Artificial Intelligence Study Of ARDS-003 Combined With Favipiravir
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra Bio-Pharma Provides Update On Patent Applications For Novel Therapeutic Ards-003
Brief: Tetra And Prepaire Jointly Apply To Barda For Funding